OBJECTIVE: Both estrogen receptors, ER alpha (ERα) and ER beta (ERβ), are expressed in 50-70% of breast cancer cases. The role of ERα as a prognostic marker in breast cancer has been well established as its expression is negative correlated with tumor size and lymph node metastasis. ERβ is also a favorable prognostic predictor although this is less well documented than for ERα. MATERIALS AND METHODS: To explore whether ERs independently or together might influence clinical outcome in breast cancer, the correlation between the ERs with the clinicopathological features was analyzed in 84 patients. RESULTS: ERα expression negatively correlated with tumor stage (r=-0.246, p=0.028) and tended to be negatively correlated with lymph node status (r=-0.156, p=0.168) and tumor size (r=-0.246, p=0.099). Also, ERβ was negatively correlated with nodal status (r=-0.243, p=0.028), as was coexpression of ERα and ERβ (p=0.043, OR=0.194, 95% CI= 0.040- 0.953). CONCLUSION: Coexpression of ERs might serve as an indicator of good prognosis in breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Han et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: